* If you want to update the article please login/register
Background: More than 25,500 women die of ovarian cancer each year, and more than 16,000 die of the disease in the United States each year. Women with a higher risk of OC have a greater lifetime risk of experiencing OC than women in the general population. In treating women with a high risk of OC [longitudinal CA-125 degrees and TVUS] and surgical techniques [risk-reducing salpingo-oophorectomy]. Objectives: To pool resources from intramural and extramural OC investigators and gather the first prospective results from high-risk women addressing the incidence of critical cancer endpoints and quality of life, determining:. How much RRSO reduces OC/Breast Cancer Risk, according to a questionnaire. How premature menopause affects the risk of developing medical issues. Or. The subject has a family history with 2 or more close blood relatives in BC, OC, or BC. With BC and/or OC and Ashkenazi Jewish ancestry, the subject has a family link to one or two close blood relatives, or. Women considering RRSO to reduce their OC risk by two-arm, non-randomized study. Women determine whether or not they should do RRSO in consultation with their physicians. Women who select RRSO have surgery under a standardized procedure. Women who have dropped RRSO are screened for OC screening with quarterly CA125/ROCA, which gives estimates of the likelihood that subjects have OC. About 800 subjects in the RRSO arm and 2,400 subjects in the screening arm have been included in the study's accrual objectives, with each of them containing at least 400 BRCA1/2 mutation carriers.
Source link: https://clinicaltrials.gov/ct2/show/NCT00043472
The aim of the initiative is to examine RRS with delayed RRO as an alternative to RRSO in BRCA1/2 gene germline mutation carriers with respect to ovarian cancer incidence. PRIMARY OBJECTIVE: To determine non-inferiority of the novel therapy as compared to the conventional treatment in BRCA1/2 gene germline mutation carriers in high risk serous cancer incidence in BRCA1/2 gene germline mutation carriers.
Source link: https://clinicaltrials.gov/ct2/show/NCT05287451
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions